We systematically examined by immune-histology the lungs of some widely used mouse models of asthma. These models include sensitization by multiple intraperitoneal injections of soluble ovalbumin (OVA) or of OVA with alum, followed by three intranasal or aerosol challenges 3 days apart. Within 24 hours after a single challenge there is fibrinoid necrosis of arterial walls with deposition of immunoglobulin and OVA and infiltration of eosinophilic polymorphonuclear cells that lasts for about 3 days followed by peribronchial B-cell infiltration and slight reversible goblet cell hypertrophy. After 2 challenges, severe eosinophilic vasculitis is present at 6 hours, increases by 72 hours and then declines; B-cell proliferation and significant goblet cell hypertrophy and hyperplasia (GCHTH) and bronchial smooth muscle hypertrophy recur more prominently. After 3 challenges, there is significantly increased induced bronchus associated lymphoid tissue (iBALT) formation, GCHTH and smooth muscle hypertrophy. Elevated levels of Th2 cytokines: IL-4, IL-5 and IL-13, are present in bronchial lavage fluids. Sensitized mice have precipitating antibody and positive Arthus skin reactions but also develop significant levels IgE antibody to OVA but only 1 week after challenge. We conclude that the asthma like lung lesions induced in these models is preceded by immune complex mediated eosinophilic vasculitis and iBALT formation. There are elevations of Th2 cytokines that most likely produce bronchial lesions that resemble human asthma. However, it is unlikely that mast cell activated atopic mechanisms are responsible as we found only a few presumed mast cells by toluidine blue and metachromatic staining limited to the most proximal part of the main stem bronchus, and none in the remaining main stem bronchus or in the lung periphery.
variations of it [1, 802 articles are listed in Pub Med under "Ovalbumin Mouse Models of Asthma"; see reviews by Cohn 2 , Zosky and Sly 3 , Nials and Uddin, 4 Kumar and Foster 5 and Mullane ad Williams 6 ]. As pointed out by Kumar et al. 7 , "There is no single "classical" model, because numerous alternatives exist with respect to the choice of mouse strain, method of sensitization, route and duration of challenge and approach to assessing the host response." The experimental approach that we utilized includes three phases: sensitization, resting and challenge. Sensitization usually consists of multiple i.p. injections of soluble OVA over a two or six week period, but may also be accomplished by subcutaneous or i.p. injection, with alum. Then the mice are "rested" for 7 to 40 days. Challenge is by intra-nasal injection or aerosol inhalation of soluble OVA, typically for 3 times with 3 days rest in between. Then 2 or 3 days after the last challenge chemical, physiologic or histologic analysis is used to evaluate the effects (for examples see Table 1 ). A prominent finding is increased airway resistance and enhanced respiratory pause after methacholine challenge (airway hyperresponsiveness, AHR) measured using a plethysmograph [8] [9] [10] . Additional findings include: increased mononuclear cells and eosinophils in bronchial lavage fluid, goblet cell hypertrophy (GCHT) of the bronchial epithelium, peribronchial mononuclear cell infiltrates in the lung, and development of bronchus associated lymphoid tissue (BALT) 11 , as well as production of circulating IgE antibody, a requirement for interleukin (IL)-4, IL-5 and IL-10 produced by CD4-Th2 cells 12, 13 , and reduction of effects if treated with beta-blockers. Interestingly, mast cells, a critical mediator of atopic asthma in humans, are not required 13 and are not increased in lungs of affected mice 14 .
Many shortcomings of this model have been pointed out and pathologic descriptions of the pulmonary lesions reported 2, [4] [5] [6] . We now show for the first time that the major initiating pathologic change is immune complex mediated eosinophilic vasculitis followed by formation of induced bronchus-associated lymphoid tissue (iBALT). These changes precede pathologic changes in the bronchi consistent with asthma, including hyperplasia and hypertrophy of bronchial mucosa, peribonchial inflammation and smooth muscle hypertrophy. A basic principle of pathology is that it is usually not possible to determine how a lesion started by examination of the lesion at a late stage. We could not find a systematic study of the early changes in the lung after a single or double pulmonary challenge. We now report that the lesions of the experimental mouse models of asthma are not initiated by mast cell degranulation but by immune complex eosinophilic vasculitis. Sensitized mice have precipitating antibody and Arthus-type reactions when skin tested with OVA. In addition, although there are elevations of serum IgE antibody to OVA 1 week after the first challenge or after the second challenge, mast cells are only found in the most proximal part of the main stem bronchus and are not seen in the distal bronchus or peripheral lung of normal or sensitized and challenged mice.
temperature and humidity in a 12 hour light/dark cycle. Purina lab chow and water were available ad lib. Mice were 7-8 weeks old at the start of each study. All experimental protocols were approved by the Wadsworth Center Animal Care Committee according to Animal Welfare Assurance Number A3183-01 of the National Institutes of Health. OVA was purchased from Sigma (catalogue number A5503).
Experimental design
Three different protocols of sensitization and challenge of mice with OVA were followed, based on methods described in the literature.
First method
A minor modification of the protocol of Hessel et al. 15 was used. Mice were sensitized by i.p. injections of 10 μg OVA (Sigma; catalogue number A5503) in 100 μL saline on alternate days for 2 weeks (seven injections) and then, 40 days after the beginning of sensitization, challenged intra-nasally with 25 μg OVA in 50 μL saline under anesthesia. Thirty-two mice were divided into three groups receiving 1, 2 or 3 challenges and 2 mice from each group euthanized at 6, 24, 72 hours and 1 and 2 weeks after challenge. Two control mice received 50 μL saline intra-nasally only. For skin testing, sensitized mice were injected in the shaved abdomen with saline on one side and 40 μg OVA (in 20 μL saline) on the other. Blood and bronchial-alveolar lavage (BAL) fluid were collected at euthanasia and then the mice were systemically perfused with 10 ml PBS. Lungs were instilled with 1 ml 4% paraformaldehyde (PFA) then immediately excised, placed in 4% PFA and dissected. Lungs and ovalbumininjected skin were placed in one cassette; spleen, thymus, intestinal sections (Peyer's patches) and saline-injected skin were placed in a second cassette. Blood was clotted at 4°C, spun down and serum collected and stored at −20°C. In addition in the second part of this experiment, 8 sensitized mice were injected intravenously (i.v.) with 500 μg OVA to determine if there might be a systemic reaction to antigen, such as anaphylactic shock. Anaphylactic shock was not elicited and no evidence of serum sickness was found.
Second method
For this model we followed the procedure published in the most recent report on the experimental asthma model that we could find 27 , with slight modification. BALB/c mice, 8 weeks old at time of first sensitization, received 6 i.p. injections of ovalbumin (10 μg in 100 μL 0.9% saline) once per week for 6 weeks and divided into three groups. Two to 3 mice were euthanized 6, 24, 48, 72 hours and 1 and 2 weeks after a single; double or triple intranasal challenge with 25 μg OVA in 50 μL saline. All mice were skin tested 6 hours prior to euthanasia and the tissues collected and processed as described above.
Third method
This method was recently described as a short model that immunized with alum and did not use the extended sensitization period used in most of the models 29 . Fourteen female BALB/c mice 6 weeks old were given a single i.p. sensitization of 100 μg of OVA in alum. On day 7 all mice were challenged intra-nasally with 100 μg of OVA. Two mice each were sacrificed at each of the following times after a single challenge: 6, 24, 48, 72 hours and 1 and 2 weeks. Controls included 2 sensitized mice that were not challenged and sacrificed at 24 hours and 2 non-sensitized, unchallenged mice. Second and third challenges were not given.
Blood, cell and tissue collection
Blood was collected from the facial vein under full anesthesia and individual drops were used to make smears on glass slides. The remaining blood was allowed to clot, then centrifuged and the serum removed and stored at −20 degrees C. The trachea was isolated, incised and an 18 gauge, blunt-ended needle was inserted to collect BAL cells, following three instillations (500 μL each) of 0.9% saline, 2.6 mM EDTA. The three samples were pooled, red blood cells lysed with ammonium chloride buffer and cytospins made on a Shandon cytocentrifuge. The systemic circulation was then perfused with 10 ml saline via the left ventricle. For tissue examination, the lungs and various organs from 4-6 mice per time point were collected and fixed in freshly prepared 4% PFA. Following automatic processing and embedding in paraffin, 5 μm sections were placed on conventional glass slides for hematoxylin and eosin staining. These slides were screened and select tissue blocks recut into serial sections for immunohistochemical analysis.
Blood Cytology
Blood smears were air-dried then stored at room temperature. Smears were fixed in methanol, serially stained with May-Grunwald (catalogue number 63550) and Giemsa (catalogue number 48900), both purchased from Sigma-Fluka Chemical Company (St. Louis, MO.) and differentiated with Sorensen's buffer, pH 6.8. In addition, smears were stained with modified Wright stain on a Hematek slide stainer. Differential counts were done microscopically under oil immersion by a certified hematology technician.
Bronchoalveolar (BAL) Cells
To detect eosinophils, cytospins were dried overnight, fixed in methanol, serially stained with eosin and methylene blue/toluidine blue (0.06 and 0.04%, respectively), then rinsed in tap water and air dried. Mast cells were detected by a 1% toluidine blue solution (see below).
BAL Fluid Cytokine Analysis
Cytokines present in the BAL fluid were analyzed using a Luminex-based system. The panel of 6 cytokines (IL-2, IL-4, IL-5, IL-12, IL-13 and interferon-γ) was chosen to sample representative Th1 and Th2 cytokines and was purchased as a kit from R & D Systems (Minneapolis, MN). Following BAL lavage to collect cells, the pooled samples were centrifuged and the supernatants decanted into cryotubes and stored at −80 ° C until analysis. Plates were prepared according to manufacturer's instructions using 50 μL of BAL fluid and cytokine levels read on a Luminex machine. Duplicate samples were analyzed from each animal. Data were pasted into an Excel file and graphed within Excel.
Histochemistry
For eosinophil detection in tissues, we followed the method of Albert et al. 30 . Briefly, 5 μm paraffin sections were rehydrated, stained 1 hour in a 1% ethanolic solution of Congo Red (Sigma; catalogue # C6767), counterstained in hematoxylin, dehydrated and mounted in Permount (Fisher Scientific, Fair Lawn, NJ; catalogue # SP15). For mast cells in tissues, two methods were used. Sections were stained either with an ethanolic 1% toluidine blue (Polysciences Inc., Warrington, PA., catalogue # 01234) solution diluted 1:10 in 1% sodium chloride or by using the thionin technique, with thionin acetate (Sigma; catalogue # T7029). Mucicarmine and periodic acid Schiff staining followed standard techniques, using ingredients purchased from Sigma (periodic acid; product # P78750), J.T. Baker, St. Louis, MO., (carmine; product number 3-E380) and MCB, Norwood, Ohio (basic fuchsin; product # BX135).
Immunohistochemistry
Serial sections on charged glass slides were rehydrated through xylenes and ethanols to water, subjected to antigen retrieval and stained with various antibodies listed in Table 2 as described previously 31 . Controls included sections treated with secondary peroxidase labeled antibody only. Signals were developed with Extravidin-peroxidase (Sigma; catalogue # E2886) and the chromogen was diaminobenzidine (Sigma; catalogue # D8001). Labeling was amplified using biotinylated tyramine, following the method of Kerstens 32 . Images were captured on an Olympus microscope, model BX51 equipped with a digital camera and Optronics Version 1.2 software. All slides were evaluated by a board certified pathologist (Dr. Sell). Control immunoperoxidase staining is shown in Supplemental Fig. 1 .
Immunodiffusion
Gel preparation and staining followed the method of Hornbek 33 . Ouchterlony plates were generated on conventional 1″ × 3″ glass slides, with an underlayer of 0.5% agar (Difco Noble agar; catalogue # 0142-01) and a top layer of 2%. Polyclonal rabbit anti-ovalbumin (catalogue # 1221) was purchased from Abcam, Cambridge, MA. Samples were pipetted into punch wells and the slides incubated 48 hours at room temperature in a humidified chamber. Gels were stained with 0.5% Coomassie Brilliant Blue R250 (Bio-Rad Laboratories, Richmond, CA.; catalogue number 161-0406), destained in 5% glacial acetic acid, 15% ethanol then air-dried and photographed.
IgE assay
IgE antibody to OVA in sera and BAL fluid was assayed by an ELISA kit for OVA-specific IgE (Chondrex Inc., Redmond, WA; kit number 3010), following the manufacturer's directions. The OVA-specific antibody was a rat monoclonal, clone 77-1. A Bio-Tek microplate reader, model EL808 was used to read the plate at 450 nM.
Statistics
Statistical differences in means were determined by one way analysis of variance (ANOVA) with Tukey's HSD (honest significant difference) test. 
Results
Histologic grading of the lung lesions at 48 hours from total of 8 experiments using 3 different models is summarized in Table 3 . There is no identifiable qualitative difference in the response to challenge after the various sensitization protocols, so that our observations are pooled for presentation.
Vascular and peribronchial inflammation after single, double and triple challenge is shown by H&E staining in Fig. 1 (See also 
Bronchial Lesions
Increasing bronchial mucosal hyperplasia and hypertrophy as well as bronchial muscular hypertrophy seen after tracheal challenge are shown in Figure 2 , and statistical analysis of measurements of changes in Table 5 . Minimal changes occur as early as 48 hours after a single challenge ( Fig. 2 E-H) but these quickly resolve if there is no further challenge. Significant submucosal muscle hypertrophy as well as bronchial mucosal hyperplasia and hypertrophy peak about 48-72 hours after the 2 nd and 3 rd challenges ( Fig. 2 .
I-K; M-O).
These gradually decrease so that by 2 weeks only a few focal areas remain.
Eosinophilic vasculitis
To confirm the nature of the PMNs in the acute vasculitis and peribronchial inflammation tissues from each challenge and time point were stained with Congo Red. Selected examples of the results are shown in Fig. 3 A-F. Twenty-four to 48 hours after a single (not shown) or double challenge most of the perivascular infiltrate is eosinophilic PMNs (Fig 3A, B) . By 72 hours (Fig. 3C) , there is an increasing number of mononuclear cells and by 1 week (Fig. 3D ) most of the perivascular cells are mononuclear. However, even after 3 challenges, when most of the perivascular and peribronchial inflammation is mononuclear (see Fig. 4 ,) eosinophils are seen in the submucosa and lumen of the bronchi ( Fig. 3 . E, F).
Mast cells
Mast cells in the lung are limited to the first high power microscopic field between the trachea and the main stem bronchus ( Fig. 3 G-J). Mast cells are not seen in either the remaining main stem bronchus or the peripheral lung of normal or sensitized and challenged mice. The number of mast cells per section ranged from 0 to 4 in normal mice to 0 to 3 after one challenge, 1 to 5 after 2 challenges and 0 to 6 after 3 challenges. Thus, mast cells may be focally increased at the tracheobronchial junction after challenge but the differences are not statistically significant.
Immunostaining for immunoglobulin (Ig) and OVA (Fig. 4)
Six hours after 1 challenge faint deposits of Ig and OVA are visible next to small vessels (see Supplemental Fig. 2 ). By 24 hours Ig deposits increase around small vessels and OVA is seen next to inflamed vessels, but OVA is mostly in alveolar macrophages ( Table 3 ).
BAL fluid cells
Staining and percentage of cell types in BAL is shown in Fig. 6 A-D. The total cell counts rose from 3 × 10 4 on day 0 to 4.5 × 10 5 on day 1, then declined gradually to 9 × 10 4 at 2 weeks. One day following intranasal challenge there is a marked increase in cells with a corresponding increase in the percentage of neutrophils and eosinophils with a decrease in monocytes. By day 3 the percentage of eosinophils increases to over 50% while the percentage of monocytes drops (Fig. 6E ). In addition, there is a marked increase in the number and size of monocyte cytoplasmic vacuoles. The percentage of eosinophils remains high for 1 week and then drops to pre-challenge levels at 2 weeks after challenge. Similar changes were recorded after triple challenge, but fewer time points are available.
Peripheral blood cells
The percentage of various white blood cells is shown in Supplemental Table 1 . The only significant changes from normal or unchallenged mice is slightly but significantly elevated eosinophils in method 2 after 2 or 3 challenges and in method 3 after 1 challenge.
IgE antibody to OVA
The titers of IgE antibody to OVA in 3 to 6 mice 48 hours and 1 week after 1, 2 or 3 challenges are shown in Fig 6 F . There is no elevation over normal in sensitized, but unchallenged mice. There is a significant difference after each challenge, with levels reaching 5 times those of unchallenged mice after 3 challenges.
Precipitating Antibody and Arthus Reaction
The serum of each mouse tested positive for precipitating antibody by double diffusion in agar (Fig. 7A ). Six hours after an injection of 40 μg of OVA into the shaved skin of each of the sensitized mice there is a grossly indurated and erythematous skin lesion ( 7F) are present in the perivascular lesions in the skin consistent with formation of immune complexes. We did not see an immediate skin reaction as described by Saloga et al. 34 that they observed after skin testing of mice sensitized by 10 consecutive inhalations of OVA.
Cytokines
There is a significant elevation of IL-5 48 hours after the first challenge and of IL-13 after all three challenges in mice sensitized according to method 2 (Supplemental Fig. 3 ). In addition, IL-4 is elevated 24 hours after challenge in the short model of sensitization (data not shown). The levels of the other cytokines measured (IL-12, IL-2 and INF-γ) are not elevated.
Discussion
According to the Mayo Clinic, asthma is a condition in which airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. According to the National Library of Medicine asthma is a respiratory condition marked by spasms in the bronchi of the lungs, causing difficulty in breathing. It usually results from an allergic reaction or other forms of hypersensitivity leading to reversible airway obstruction, airway hyperactivity and airway inflammation. These and other functional descriptions of asthma include a broad spectrum of conditions that may be useful clinically, but essentially ignore various possible differences in pathologic mechanisms and tissue pathology. Human acute asthma, for example, is included in the immunopathologic category of atopic or anaphylactic reactions unleashed when allergen reacts with and cross-links IgE receptors on mast cells 35 . Repeated activation of this mechanism results in the pathologic features of chronic human asthma: hyperplasia of bronchial smooth muscle, hyperplasia of bronchial mucous cells, chronic peribronchial inflammation with increased mast cells and thickening of the basement membrane of the bronchial mucosa 35 . Herein we show that the ovalbumin mouse model of asthma has features of immune complex disease which cast doubt on its validity as a model for asthma. Bronchial lesions consistent with asthma (mucosal hyperplasia and hypertrophy and hyperplasia of bronchial smooth muscle) are preceded by immune complex vasculitis and iBALT formation. It is not clear why lesions typical of asthma are induced by an immune complex reaction; elevation of Th2 type cytokines that induce asthma like inflammation is seen but these are not usually associated with Th1 type immune complex reactions. Elevations of serum IgE suggest that some atopic-like Th2 mechanism may become active after the initial Th1 reaction, but the lack of mast cells in most of the major bronchus and lung periphery rule against this.
Immune complex eosinophilic vasculitis
The early lesions induced by a single injection of antigen into the lung of mice sensitized to produce the mouse model of asthma are fibrinoid necrosis of arterial walls and infiltration of eosinophilic PMNs. There is no evidence of acute bronchial constriction or mucous hyperplasia characteristic of acute human asthma at this time, although hyperplasia and hypertrophy of mucous cells begins about 3 days after primary challenge. We consider the acute vasculitis to be immune complex mediated except that the inflammatory cells are up to 70% eosinophilic PMNs rather than neutrophilic. Mice sensitized by multiple OVA injections or a single injection In alum demonstrate Arthus skin reactions 36 when skin tested by injection of OVA. The sera of these mice contain high titers of precipitating antibody as detected by double-diffusion-in-agar and both Ig and OVA are present in the vascular lesions of the skin as well as the vascular lesions of the lung. Immune complex vasculitis has been repeatedly demonstrated when soluble protein antigen is injected into the trachea of experimental animals either actively of passively immunized with antibody to the antigen.
Active pulmonary Arthus reactions
Active Arthus reactions in the lung were employed from 1912 to 1972 to determine the effect of immune complex induced injury [37] [38] [39] [40] [41] [42] [43] [44] . This involved active immunization followed by pulmonary challenge with antigen. For example, Schlecht and Schwenker 37 saw pulmonary hemorrhage and acute alveolitis in immunized guinea pigs after inhalation of horse serum. Opie 38 , repeated the approach in the lung originally described by Arthus in 1903 for the skin. In rabbits that had been immunized by repeated injections of horse serum, injection of horse serum into the lung produced "an acute localized consolidation with leucocytes and edema surrounding a central focus of necrosis." Most of Opie's studies were done on skin reactivity where he found that the reaction depends on the titer of precipitating antibody. In rabbits immunized to ovalbumin, Cannon and Walsh 40 describe alveolitis and bronchitis featuring vasculitis, but the histologic findings are not described. Fried 39 observed an influx of "granulocytes" 12 to 15 hours after intratracheal injection of horse serum into immunized rabbits. Eosinophils were also seen, but "on rare occasions". The reaction peaked at 24 to 36 hours and then gradually subsided. This is essentially what we describe in OVA sensitized mice following a single intranasal injection of OVA, except for the predominance of eosinophils seen in our study. The suggestion that active Arthus reactions in the lung might have similarities to asthma was made by Kallos and Kallos, 1984 45 , on the basis of an influx on eosinophils in the lungs of sensitized and challenged guinea pigs (see also Kung et al. 16 ). However, Sanjar et al., 46 noted that there is no evidence for a causal relationship between increased airway reactivity and eosinophilia in this model. The application of this model has extended to two divergent approaches: i, using passive reverse Arthus reactions in the lung to study the mechanisms involved in immune complex inflammation and ii, in mice as a model for asthma.
Reverse passive Arthus reactions in the lung
A number of laboratories have used a reverse passive Arthus reaction in the lung introduced by Ward and collaborators [47] [48] [49] [50] [51] to identify components of the early immune complex initiated inflammatory reaction. The standard protocol for this model is to inject antibody into the trachea followed within minutes by injection of antigen (bovine serum albumin or OVA) intravenously. Within 4 to 6 hours a neutrophil-rich exudate develops in alveolar and interstitial areas and then gradually fades. Deposits of antigen and antibody may be identified in the involved areas. Antibody, complement (C3), neutrophils and release of oxygen radicals are required 47 . The inflammatory lesions are not localized perivascularlly as in the model described in the asthma models in this paper, since the antibody-antigen reaction takes place in the airway and not the vasculature. This inflammation is blocked by superoxide dismutase 48 , but enhanced by tumor necrosis factor (TNF) released from resident macrophages 49 . It requires interaction between neutrophils and endothelial cells mediated by endothelial-leukocyte adhesion molecule1 50 , β 2-integrins 51 , and endothelins, C3 and mast cells 52 ; urokinase/urokinase receptors 53 , FcγR-mediated TNF-α and CXCR2 ligand (CXCR2L) production 54 , and Gα i2 protein-coupled C5a receptor which regulates IgG FcR function and enhances transmigration of neutrophils into inflammatory lesions 55 . The key is the early C5aR-Gi-dependent signal for FcγRIII activation, local synthesis of TNF-α and CXCR2L leading to recruitment of PMNs. The factors responsible for eosinophic infiltration in our studies are under investigation.
Why eosinophilic vasculitis?
Most of the studies using the mouse models of asthma describe a marked increase in eosinophils, in bronchial lavage fluid 28 , but not a significant increase in the peripheral blood (0 in controls to up to 0.1% in blood after challenge) whereas there is a marked increase in neutrophils in the blood (from 16% in controls to 28% in sensitized and three times challenged mice 56 . This is more consistent with a Th1 type response (immmune complex) than a Th2 type response (atopic). The precise role of eosinophils in asthma is not clear. They may only be bystander cells or may contribute toxicity to the bronchial epithelium and to bronchoconstriction 57 . A role for eosinophils is supported by the finding that the inflammation produced by the OVA challenge model is greatly reduced in mice depleted of eosinophils 58, 59 . However, the striking eosinophilic vasculitis has not been described previously because previous studies were done after 3 OVA challenges. We show that eosinophilic vasculitis is readily seen after 1 or 2 OVA challenges, but is essentially replaced by mononuclear vasculitis after 3 challenges (Figs. 1 and 3 ). Although there is early fibrinoid necrosis, there appears to be little damage to bronchial epithelium or surrounding tissue and the lesions resolve quickly. Eosinophils contain at least 5 preformed enzymatic and non-enzymatic granular proteins that contribute to airway damage, inflammation and tissue remodeling 60 . However, degranulation and peroxidase-mediated oxidation of airway proteins do not appear to play a significant role in OVA-induced inflammation in the mouse as mice deficient for eosinophil peroxidase display the same AHR and pathologies as wild-type mice 61 .
The accumulation of eosinophils in the lung instead of neutrophils that would be expected in an immune complex vasculitis is most likely mediated by CCL11 (chemokine C-C motif ligand 11, also called eotaxin), by Th2 cytokines (e.g. IL-5) and by IL-23. CCL11 is increased in the OVA mouse model of asthma associated with AHR and pulmonary eosinophilia [62] [63] [64] . Levels of CCL11 are consistently higher in asthmatic patients versus controls 65 . IL-23 is produced by activated macrophages and dendritic cells and stimulates IL-17 and IL-22 secretion from innate immune cells 66 . Eosinophilic infiltrate is increased in transgenic mice overexpressing the IL-23 receptor 67, 68 , expression of eosinophilic peroxidase is greatly decreased in OVA challenged IL-23 knockout mice compared to WT mice 69 , and inhibition of IL-23 release inhibits airway inflammation 70 reduces AHR and the number of eosinophils in BAL after OVA challenge 71 . We propose that activation of IL-23 may be enhanced by uptake by and activation of alveolar macrophages by OVA in sensitized mice. Activation of CCL11, IL-5 and IL-23 in the lung may explain why the acute inflammatory response to OVA challenge in the lung is eosinophilic, whereas that in the skin reaction is predominantly neutrophilic 35, 36 . IL-23 is most likely not activated in previously unchallenged skin and CCL11 is secreted by epithelial cells in the lung that are not present in the dermis of the skin.
Goblet cell hypertrophy and hyperplasia (GCHTH), a prominent feature in OVA challenged mice, is first seen 3 days after the first challenge Fig. 2 ). GCHTH is most likely stimulated by IL-17 72 and other Th2 cytokines, such as IL-13 and IL-33 73 as well as NF-κB 74 . GCHT and increased intrabronchial mucous most likely affects changes in air exchange but it is not clear how this affects airway hypersensitivity. In most reports of the mouse models goblet cell hyperplasia is described. Our histologic analysis indicates an increase in size and mucous content of goblet cells (hypertrophy) and hyperplasia (increase in cell number) as well as smooth muscle hypertrophy.
Where are the mast cells?
In human allergic reactions, binding of the allergen to IgE on mast cells with subsequent release of mediators is the classic mechanism of the acute asthmatic response and increased numbers of mast cells are present in the peribronchial inflammation seen in chronic asthma. Mast cells are not increased in OVA challenged mice 24 , and, are very rarely seen in normal mouse lung 75 . However, mast cells have been described if sensitized mice are re-challenged repeatedly with OVA for 1 to 6 months 76 . In the present study, mast cells were easily identified in the skin. However upon careful scanning sections selected to include the trachea and main stem bronchus of normal and inflamed lungs, 0 to 6 mast cells were seen only in the most proximal part of the main stem bronchus (Fig. 3 G-J) . This is consistent with the findings of Haile et al. 77 that mast cells could be found in the connective tissue between the large vessels and the bronchi, but not in the smaller bronchi or alveolar tissue. They also did not see an increase in mast cells after challenge. Mast cells have been identified in the lungs and BAL of C57BL/6 mice by Fuchs et al. 78 , but the role of these in AHR is not definitive. They found that AHR was not different in wild type and mast celldeficient mice after OVA challenge, but reactivity in mast cell-deficient mice was increased after engraftment of bone marrow derived mast cells. This interesting result suggests that putative resident mast cells in the lung, if present, do not contribute to AHR, but that transferred mast cells from the bone marrow do.
iBALT formation
BALT is an adaptive immune response in the lung and is a site where local immune responses can occur rapidly after exposure to inhaled antigens. BALT is a constitutive mucosal lymphoid tissue in rats and rabbits, but is not present normally in humans or mice. However, BALT is inducible in humans and mice after inflammation in the lung 79, 80 , socalled inducible BALT (iBALT). iBALT is seen in chronic lung infections in humans 81 , as well as in mice with repeated virus infections of the lung 82 . iBALT has also been described in humans with asthma 83 . Mice lacking spleen, lymph nodes and Peyer's patches develop iBALT in response to influenza challenge, clear influenza infection and, when BALT is present, survive higher doses of the virus than do normal mice 84 . The presence of iBALT in response to one viral infection enhances the immune response to subsequent infection with unrelated viruses (heterologous immunity 82 ). Thus, BALT may be considered a local site for immune memory that can respond quickly to a second pulmonary infection. IL-5 and IL-17, both elevated in OVA sensitized mice 24, 67, [85] [86] [87] [88] , may act synergistically to stimulate iBALT formation. IL-5 increases B-cell proliferation 89 . IL-17 increases expression of the chemokines CXCL12 and CXCL13 90 which are critical for follicle formation 91 with or without the participation of dendritic cells 92 . Thus, the late histologic changes in the OVA mouse lung inflammation model appear to be mediated by Th2 and Th17 cytokines and are rapidly reversed when these cytokines are no longer secreted.
Comparison to human pulmonary vasculitis
It is not clear how this experimental induction of chronic vascular and peribronchial inflammation in the lung in mice compares to naturally occurring pulmonary vasculitis in humans 93, 94 . The lesions produced involve what would be considered medium-sized vessels in humans. This makes the small-vessel vasculitides associated with anti-neutrophil cytoplasmic antibody (ANCA) and the large vessels lesions such as Giant cell arteritis and Takayasu's arteritis, unlikely candidates. Churg-Strauss syndrome is a likely candidate 95 . Also known as eosinophilic granulomatosis with polyangitis or allergic granulomatosis, this syndrome features high numbers of eosinophils and eosinophilic vasculitis in the lung associated with asthma and/or allergic rhinitis 96 . The lesions of adult respiratory distress syndrome (ARDS) involve small vessels and result in damage to the alveolar-capillary membrane 97 , which is not seen in this model. The most likely associations for the acute lesions would be with primary immune complex-mediated vasculitis, such as Goodpasture's syndrome involving the lung, polyarteritis nodosa or serum sickness. However, there may be no naturally occurring lesions in the lung that correspond to those produced by the massive and multiple doses of soluble antigen to sensitized mice.
Final comments
Of what use is the study of the physiologic changes or pharmacologic alterations of the mouse model of asthma for understanding human asthma? Clearly the sensitization and bronchial challenge of mice with OVA produces histologic changes in the bronchi consistent with human asthma. Thus, it could be argued that, even though the basic pathologic mechanism (immune complex vasculitis) is different from that of human asthma (atopic or anaphylactic), identifying physiologic mechanisms or efficacious treatment might be possible using this model. The role of an atopic mechanisms in producing the bronchial lesions is unclear. Although IgE antibody becomes elevated after the first challenge, it is not elevated in sensitized, unchallenged mice and mast cells are only seen in the most proximal main stem bronchi and not in the remaining main stem bronchi or more distal bronchi where the asthma-like hypertrophy and hyperplasia of mucosa cells and smooth muscle hypertrophy is seen.
On the other hand, intervention directed against the underlying pathogenic mechanism of human asthma would not be possible in the mouse model because the reaction responsible for the lesions of the mouse model of asthma is not the same as for human asthma. For example, one of the possible mechanisms thought to mediate desensitization of allergic reactions by immunizing with the allergen is an attempt to shift the immune response from IgE antibody to IgG antibody. In this approach, the IgG antibody prevents the allergen from reacting with IgE on mast cells and thus inhibits the atopic reaction. However, in the mouse model it appears that IgG antibody actually initiates the pathologic response to OVA challenge; precipitating antibody is present in sensitized, unchallenged mice at a time when IgE antibody is not yet elevated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Table 5 shows the measurements and statistical analysis. Clearly by the second challenge there are lesions associated with asthma including mucosal hyperplasia and hypertrophy and hypertrophy of submucosal smooth muscle. There is a significant increase in mucosal cell nuclei at 48 hours after 2 and 3 challenges (p<01); in mucosal thickness and submucosal smooth muscle thickness after each challenge (p<01) as well as significant increases from one challenge to the next. Table 2 Antibodies used to label tissue sections. Table 3 Average histologic grade of reactions (0 to 3) at 48-72 hours. Table 5 Goblet cell hyperplasia and Hypertrophy and bronchial smooth muscle hypertrophy. 
